J. B. Chemicals & Pharmaceuticals Limited has reported its financial performance for the year ended March 31, 2026. The company achieved standalone revenue of ₹3,88,989 lakhs and a net profit after tax of ₹67,410 lakhs. The Board of Directors has recommended a final dividend of ₹9.30 per equity share for the fiscal year 2025-26, reflecting the company’s strong operational focus and commitment to delivering value to its shareholders.
Annual Financial Highlights
For the financial year ended March 31, 2026, J. B. Chemicals & Pharmaceuticals reported robust growth. The company’s standalone revenue reached ₹3,88,989 lakhs, compared to ₹3,72,292 lakhs in the previous year. Net profit after tax for the full year stood at ₹67,410 lakhs, demonstrating steady performance compared to ₹65,254 lakhs reported in the prior fiscal year.
Consolidated Performance
On a consolidated basis, the company reported a total income of ₹4,20,794 lakhs for the year. The net profit attributable to owners of the company for the same period was ₹70,947 lakhs, marking a significant milestone in the company’s operational journey. The consolidated earnings per share (basic) for the year stood at ₹45.16.
Shareholder Returns and Corporate Updates
In view of the company’s performance, the Board of Directors has recommended a final dividend of ₹9.30 per equity share (face value of ₹1 each) for the year 2025-26. Additionally, the company continues to make progress on its proposed scheme of amalgamation with Torrent Pharmaceuticals Limited, having received approval from equity shareholders in a meeting held on April 28, 2026.
Strategic Focus
The company maintains a strong focus on its core pharmaceutical business segment. During the final quarter of the year, exceptional items were recorded, including ₹1,872.82 lakhs in severance compensation due to distribution network restructuring and ₹845 lakhs attributed to impacts from the introduction of new labour codes.
Source: BSE
